HUA MEDICINE-B (02552) saw its stock soar 5.88% in intraday trading, continuing its upward momentum following the release of its impressive interim results. The company reported its first-ever profit during a reporting period, marking a significant milestone in its commercialization efforts.

The stellar performance can be attributed to several factors. Huatangning, the company's key product, saw sales surge by 108% year-over-year to 1.764 million boxes, while net sales jumped 112% to 217.4 million yuan. The termination of its exclusive promotion service agreement with Bayer resulted in a one-time recognition of 1.2435 billion yuan in deferred revenue, contributing to a first-half profit of 1.1839 billion yuan. Moreover, improved operational efficiency and expanded production scale boosted the gross margin to 54.2%, up 7.7 percentage points from the previous year.

Looking ahead, HUA MEDICINE's prospects appear promising. Since taking full control of Huatangning's commercial operations in January 2025, the company has achieved remarkable growth through its independent sales team. The expansion of medical insurance coverage has led to increased prescription volumes in secondary and tertiary hospitals. Additionally, the company is actively expanding its overseas business and accelerating its global expansion strategy while continuing to invest heavily in R&D, providing a solid foundation for future growth.